Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment

Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment

New tools are needed to match cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform to personalize treatments and discover novel therapies. Currently, methods to evaluate drug response in organoids are limited because they overlook cellular heterogenei...

Full description

Bibliographic Details
Main Authors: Joe T. Sharick, Christine M. Walsh, Carley M. Sprackling, Cheri A. Pasch, Dan L. Pham, Karla Esbona, Alka Choudhary, Rebeca Garcia-Valera, Mark E. Burkard, Stephanie M. McGregor, Kristina A. Matkowskyj, Alexander A. Parikh, Ingrid M. Meszoely, Mark C. Kelley, Susan Tsai, Dustin A. Deming, Melissa C. Skala
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
pancreatic cancer
breast cancer
organoid
optical metabolic imaging
heterogeneity
cellular metabolism
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00553/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00553/full

Similar Items